17.75
price down icon4.55%   -0.845
 
loading
전일 마감가:
$18.59
열려 있는:
$18.97
하루 거래량:
1.18M
Relative Volume:
0.40
시가총액:
$819.84M
수익:
$82.71M
순이익/손실:
$-102.24M
주가수익비율:
-4.8351
EPS:
-3.67
순현금흐름:
$-76.57M
1주 성능:
-8.53%
1개월 성능:
+29.43%
6개월 성능:
+65.53%
1년 성능:
+18.38%
1일 변동 폭
Value
$17.45
$18.97
1주일 범위
Value
$17.07
$21.02
52주 변동 폭
Value
$3.42
$21.02

Urogen Pharma Ltd Stock (URGN) Company Profile

Name
명칭
Urogen Pharma Ltd
Name
전화
972 9 770 7601
Name
주소
9 HA'TA'ASIYA ST, RA'ANANA
Name
직원
234
Name
트위터
@UroGenPharma
Name
다음 수익 날짜
2025-03-10
Name
최신 SEC 제출 서류
Name
URGN's Discussions on Twitter

URGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
URGN
Urogen Pharma Ltd
17.75 924.49M 82.71M -102.24M -76.57M -3.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-16 업그레이드 H.C. Wainwright Neutral → Buy
2025-05-22 다운그레이드 H.C. Wainwright Buy → Neutral
2025-04-16 개시 Scotiabank Sector Outperform
2025-02-19 재개 Ladenburg Thalmann Buy
2024-08-22 개시 Guggenheim Buy
2023-02-08 다운그레이드 Jefferies Buy → Hold
2022-04-27 개시 Berenberg Buy
2020-04-16 재확인 H.C. Wainwright Buy
2020-04-13 재확인 H.C. Wainwright Buy
2020-01-09 개시 National Securities Neutral
2019-05-30 개시 JP Morgan Neutral
2019-05-29 개시 Goldman Neutral
2019-01-29 개시 H.C. Wainwright Buy
2018-11-08 재개 Jefferies Buy
2018-04-04 업그레이드 Raymond James Mkt Perform → Outperform
2018-01-02 개시 Ladenburg Thalmann Buy
2017-11-15 재확인 Oppenheimer Outperform
2017-11-15 다운그레이드 Raymond James Outperform → Mkt Perform
모두보기

Urogen Pharma Ltd 주식(URGN)의 최신 뉴스

pulisher
Aug 09, 2025

UroGen Pharma's Q2 2025 Earnings: A Catalyst for Valuation Re-Rating in Uro-Oncology? - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

UroGen Pharma Q2 2025 Earnings Call Transcript - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

UroGen Pharma Ltd. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:URGN) - Seeking Alpha

Aug 09, 2025
pulisher
Aug 08, 2025

Oppenheimer Maintains Buy Rating on Urogen Pharma with $31 Price Target - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Guggenheim raises UroGen Pharma stock price target to $32 on Zusduri launch - Investing.com Australia

Aug 08, 2025
pulisher
Aug 08, 2025

UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

UroGen Pharma Q2 Earnings Call: FDA Approval, Revenue Growth, and Expanded Sales Force - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA A - GuruFocus

Aug 08, 2025
pulisher
Aug 07, 2025

Urogen Pharma Q2 2025 Earnings Call Transcript - MarketBeat

Aug 07, 2025
pulisher
Aug 07, 2025

Health Care Stocks Slipped As Big Players Disappointed - Finimize

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma (URGN) Receives Consistent "Buy" Rating from D. Boral Capital | URGN Stock News - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma Tops Revenue Forecasts With FDA Approval In Tow - Finimize

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma Outpaces Forecasts With Revenue And FDA Nod - Finimize

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth - Investing.com

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: UroGen Pharma Q2 2025 results show revenue growth By Investing.com - Investing.com South Africa

Aug 07, 2025
pulisher
Aug 07, 2025

Urogen Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma falls as wider-than-expected Q2 loss overshadows revenue beat - Investing.com

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma earnings missed by $0.22, revenue topped estimates - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDUR - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings Flash (URGN) UroGen Pharma Posts Q2 Net Loss $1.05 a Share, vs. FactSet Est of $0.83 Loss - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma Ltd. SEC 10-Q Report - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q2 Revenue $24.2M, vs. FactSet Est of $23.1M - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma Expands Commercial Portfolio with Launch of - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results - Yahoo Finance

Aug 07, 2025
pulisher
Aug 06, 2025

UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revis - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

UroGen Pharma (URGN) Q2 Earnings Preview: Expectations and Revisions - GuruFocus

Aug 06, 2025
pulisher
Aug 06, 2025

UroGen’s Zusduri benefit maintained in NMIBC Phase III study - Yahoo Finance

Aug 06, 2025
pulisher
Aug 05, 2025

URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

D. Boral Capital Maintains Buy Rating for UroGen Pharma with $25 Price Target - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bla - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

URGN: D. Boral Capital Maintains Buy Rating and $25 Price Target | URGN Stock News - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

UroGen Pharma (URGN) Highlights Promising Long-Term Data for Bladder Cancer Treatment - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

UroGen Pharma: D. Boral Capital maintains Buy, PT raised to $25 from $25. - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - GlobeNewswire

Aug 05, 2025
pulisher
Aug 05, 2025

Breakthrough: New Bladder Cancer Drug Shows 72% Success Rate in Phase 3 Trial Results - Stock Titan

Aug 05, 2025
pulisher
Aug 03, 2025

What institutional investors are buying UroGen Pharma Ltd. stockAchieve superior returns through strategic trading - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is UroGen Pharma Ltd. company’s balance sheetPhenomenal capital gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is UroGen Pharma Ltd. company’s growth strategyAchieve superior capital gains with smart trades - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Does UroGen Pharma Ltd. stock perform well during market downturnsInvest confidently with professional advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about UroGen Pharma Ltd.Rapid portfolio appreciation - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is UroGen Pharma Ltd. a growth stock or a value stockAchieve consistent profits with expert advice - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell UroGen Pharma Ltd. stock in 2025Unlock exclusive stock market forecasts - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What markets is FTAIN expanding into Is UroGen Pharma Ltd. stock a good long term investment optionDouble or triple returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive UroGen Pharma Ltd. stock higher in 2025Build wealth steadily with proven investment techniques - Jammu Links News

Aug 03, 2025
pulisher
Aug 01, 2025

How does UroGen Pharma Ltd. compare to its industry peersRetirement Planning Alerts That Work - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

Is UroGen Pharma Ltd. stock overvalued or undervaluedBreakout Stocks Strategy With Low Risk - jammulinksnews.com

Aug 01, 2025
pulisher
Jul 31, 2025

What markets is UroGen Pharma Ltd. expanding into Is CPRX stock a good long term investment optionExpert Picks Forecasts Backed By Experts - Jammu Links News

Jul 31, 2025

Urogen Pharma Ltd (URGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$78.39
price up icon 0.24%
$37.58
price up icon 1.54%
$109.55
price up icon 0.23%
$28.66
price up icon 2.10%
$111.66
price up icon 0.28%
biotechnology ONC
$288.18
price down icon 3.39%
자본화:     |  볼륨(24시간):